Zydus Cadila, one of India's leading healthcare companies, will be launching Etoricoxib, a new generation pain relieving therapy under the brand name Nucoxia. Etoricoxib is among the second-generation drugs, which are being used increasingly in the treatment of acute and chronic pain.
Nucoxia, according to the company, has a two pronged action. It offers a quick onset of action and also sustains itself for a longer period - for as long as 24 hours, according to the company. The company also says that daily dosage once is very convenient, making it an ideal therapy for acute pain management.
Zydus identifies pain management as one of the core areas of the group. Zydus was also the first to launch the Celecoxib drug (Zycel) in the country.